A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Crenezumab (Primary) ; Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms BLAZE
  • Sponsors Genentech
  • Most Recent Events

    • 25 Jul 2018 Results published in the Genentech Media Release
    • 25 Jul 2018 According to Genentech media release, data from this trial werepresented at the Alzheimer's Association International Conference (AAIC).
    • 19 Jul 2018 According to Genentech media release, data from this trial will be presented at the Alzheimer's Association International Conference (AAIC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top